Workstream Type: Informing Dialogue
-
A $475,000 price tag for a new cancer drug: crazy or meh?
Read More
-
US Drug Prices And R&D, Take 2: A Reply To Grabowski And Manning, And To Light
Read More
-
Baseball Illuminates the Problem with U.S. Drug Pricing
Read More
-
DPL and Collaborators to Publish Drug Pricing Primer Series
Read More
-
Is Outcomes-Based Contracting Worth It?
Read More
-
Copay Assistance: Doing More Harm Than Good?
Read More
-
A Q&A with Peter Bach
Read More
-
Expensive Oral Agents Responsible for Cost Shifting in Cancer
Read More
-
The Insurance Companies’ Latest Target: Specialty Drugs
Read More
-
Dr Steve Miller Highlights the Importance of Working Closely With Oncologists
Read More